Blogs
- Q3’26 Psychedelic Drug Development Pipeline: Bullseye Charts
- Field Notes #3: Washington’s Busy Week, and the Biggest Psychedelic Buyout Yet
- Breaking: World’s Largest Pharmaceutical Company, Eli Lilly, Acquires 5-MeO-DMT Developer AtaiBeckley for Up to $3.8 billion
- Backed by $11M NIDA Grant, Harvard Moves Forward on Ibogaine for Opioid Use Disorder Research
- Keeping Up with the Feds: From FDA to HRSA, Washington Backs Psychedelics
- FDA Issues Final Psychedelics Guidance, Schedules September Hearing on the Future of Psychedelic Therapies
- Pα+ Psychedelic Bulletin #227: A Closer Look at Compass’ 6-Month Data; AtaiBeckley Deal Update; ‘Rysanso’ Brand MDMA?
- Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27 Launch
- Quarterly Psychedelics Briefing: Q2 2026
- Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics
- A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report
- ‘A Sea Change’, With Caveats: A Closer Look at Definium’s Phase 3 LSD for MDD Readout
- Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect
- The Psychedelic Practitioner Issue 5: Groups in Practice
- Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities
Magazines
- Q3’26 Psychedelic Drug Development Pipeline: Bullseye Charts
- Field Notes #3: Washington’s Busy Week, and the Biggest Psychedelic Buyout Yet
- Breaking: World’s Largest Pharmaceutical Company, Eli Lilly, Acquires 5-MeO-DMT Developer AtaiBeckley for Up to $3.8 billion
- Backed by $11M NIDA Grant, Harvard Moves Forward on Ibogaine for Opioid Use Disorder Research
- Keeping Up with the Feds: From FDA to HRSA, Washington Backs Psychedelics
- FDA Issues Final Psychedelics Guidance, Schedules September Hearing on the Future of Psychedelic Therapies
- Pα+ Psychedelic Bulletin #227: A Closer Look at Compass’ 6-Month Data; AtaiBeckley Deal Update; ‘Rysanso’ Brand MDMA?
- Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27 Launch
- Quarterly Psychedelics Briefing: Q2 2026
- Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics
- A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report
- ‘A Sea Change’, With Caveats: A Closer Look at Definium’s Phase 3 LSD for MDD Readout
- Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect
- The Psychedelic Practitioner Issue 5: Groups in Practice
- Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities
Record Labels
- Q3’26 Psychedelic Drug Development Pipeline: Bullseye Charts
- Field Notes #3: Washington’s Busy Week, and the Biggest Psychedelic Buyout Yet
- Breaking: World’s Largest Pharmaceutical Company, Eli Lilly, Acquires 5-MeO-DMT Developer AtaiBeckley for Up to $3.8 billion
- Backed by $11M NIDA Grant, Harvard Moves Forward on Ibogaine for Opioid Use Disorder Research
- Keeping Up with the Feds: From FDA to HRSA, Washington Backs Psychedelics
- FDA Issues Final Psychedelics Guidance, Schedules September Hearing on the Future of Psychedelic Therapies
- Pα+ Psychedelic Bulletin #227: A Closer Look at Compass’ 6-Month Data; AtaiBeckley Deal Update; ‘Rysanso’ Brand MDMA?
- Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27 Launch
- Quarterly Psychedelics Briefing: Q2 2026
- Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics
- A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report
- ‘A Sea Change’, With Caveats: A Closer Look at Definium’s Phase 3 LSD for MDD Readout
- Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect
- The Psychedelic Practitioner Issue 5: Groups in Practice
- Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities
News stories about record stores
- Q3’26 Psychedelic Drug Development Pipeline: Bullseye Charts
- Field Notes #3: Washington’s Busy Week, and the Biggest Psychedelic Buyout Yet
- Breaking: World’s Largest Pharmaceutical Company, Eli Lilly, Acquires 5-MeO-DMT Developer AtaiBeckley for Up to $3.8 billion
- Backed by $11M NIDA Grant, Harvard Moves Forward on Ibogaine for Opioid Use Disorder Research
- Keeping Up with the Feds: From FDA to HRSA, Washington Backs Psychedelics
- FDA Issues Final Psychedelics Guidance, Schedules September Hearing on the Future of Psychedelic Therapies
- Pα+ Psychedelic Bulletin #227: A Closer Look at Compass’ 6-Month Data; AtaiBeckley Deal Update; ‘Rysanso’ Brand MDMA?
- Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27 Launch
- Quarterly Psychedelics Briefing: Q2 2026
- Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics
- A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report
- ‘A Sea Change’, With Caveats: A Closer Look at Definium’s Phase 3 LSD for MDD Readout
- Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect
- The Psychedelic Practitioner Issue 5: Groups in Practice
- Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities